| Titolo |
Pubblicato in |
Anno |
| New driver alterations in non-small cell lung cancer: A narrative review |
PRECISION CANCER MEDICINE |
2022 |
| Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study |
TUMORI |
2022 |
| A regional survey on Merkel cell carcinoma: a plea for uniform patient journey modeling and diagnostic–therapeutic pathway |
CURRENT ONCOLOGY |
2022 |
| Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index |
EUROPEAN JOURNAL OF CANCER |
2021 |
| Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives |
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY |
2021 |
| Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives |
CANCERS |
2021 |
| Drug–drug interactions and pharmacogenomic evaluation in colorectal cancer patients: The new drug-pin® system comprehensive approach |
PHARMACEUTICALS |
2021 |
| The role of opioids in cancer response to immunotherapy |
JOURNAL OF TRANSLATIONAL MEDICINE |
2021 |
| Standard of care and promising new agents for the treatment of mesenchymal triple-negative breast cancer |
CANCERS |
2021 |
| CT based radiomic approach on first line pembrolizumab in lung cancer |
SCIENTIFIC REPORTS |
2021 |
| New immunological potential markers for triple negative breast cancer: IL18R1, CD53, TRIM, Jaw1, LTB, PTPRCAP |
DISCOVER ONCOLOGY |
2021 |
| Evaluation of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors |
JOURNAL OF PERSONALIZED MEDICINE |
2021 |
| H-Ras gene takes part to the host immune response to COVID-19 |
CELL DEATH DISCOVERY |
2021 |
| Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era |
JOURNAL OF TRANSLATIONAL MEDICINE |
2021 |
| Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view |
CLINICAL & TRANSLATIONAL ONCOLOGY |
2021 |
| A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer |
CURRENT ONCOLOGY |
2021 |
| The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study |
JOURNAL OF PERSONALIZED MEDICINE |
2021 |
| Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study |
BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE |
2021 |
| Anti–PD-1 and Anti–PD-L1 in head and neck cancer: a network meta-analysis |
FRONTIERS IN IMMUNOLOGY |
2021 |
| Individualized drugs’ selection by evaluation of drug properties, pharmacogenomics and clinical parameters. Performance of a bioinformatic tool compared to a clinically established counselling process |
PHARMACOGENOMICS AND PERSONALIZED MEDICINE |
2021 |
